In The Good, The Bad, and The Ugly: One analyst's buy rating on Alibaba stock; the government's rough housing numbers; and the Apple CEO's privacy push» Read More
No, Alibaba doesn't actually cure cancer; however, you would think so as some traders say it's lifting stocks ahead of its IPO tomorrow.
Showing up to work high? You're not alone. A new report has found nearly 1 in 10 Americans are showing up to work high on marijuana. The Squawk Box crew discusses the story.
With plenty of vacant homes, there’s just not enough demand to necessitate building more new homes. So why are they being built?
There are several reasons I am optimistic that Alibaba—at whatever price—will open to the upside and stay there.
CNBC's Jim Cramer explains why he doesn't want to see Alibaba open above $80 per share when it comes public on Friday.
Paul Ingrassia, Reuters managing editor, weighs in on why truck sales are in overdrive.
Pick-up and SUV sales are booming while car sales have dropped, reports CNBC's Phil LeBeau.
Stephen Paul, Mid-Atlantic Builders, provides insight on the surging home builder's space.
CNBC's Steve Liesman, and BlackRock's Jeffrey Rosenberg, discuss whether the Fed is sending mixed messages to the markets.
CNBC's Rick Santelli breaks down the latest data on unemployment and housing. Housing starts dropped 14.4 percent in August, reports Santelli.
CNBC's Steve Liesman does the math on the Fed's policy statement on Wednesday. And BlackRock's Jeffrey Rosenberg, weighs in.
CRT Capital Group's Neil Doshi has a buy rating on Alibaba and a $95 price target. This is the largest e-commerce play in the world, says Doshi.
CNBC's Josh Lipton reports on what Alibaba's historic public debut means for Yahoo's stake in the company.
CNBC's Susan Li takes a look at Alibaba's long term plans and why the e-commerce giant is coming to New York.
CNBC's Michelle Caruso-Cabrera reports the latest news on Scotland's vote for independence.
John Rutledge, Safanad chief investment strategist, and Gordon Chang, "The Coming Collapse of China," author, discuss the dangers associated with investing in China.
Gordon Chang, "The Coming Collapse of China," author, shares his thoughts on the risks associated with investing in Alibaba's IPO.
The man can mesmerize an audience, says John Rutledge, Safanad chief investment strategist, sharing his thoughts on the Chinese business leader and discussing his concerns about investing in Alibaba's IPO. Don't buy something you don't understand, Rutledge warns investors.
According to a new report nearly ten percent of Americans go to work high, reports CNBC's Kate Rogers.
CNBC's Jon Fortt reports the latest details on Amazon's new product line.
Get the best of CNBC in your inbox